Q1 2025 13F Holders as of 31 Mar 2025
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
86,559,040
-
Total 13F shares
-
100,841,762
-
Share change
-
+3,013,035
-
Total reported value
-
$1,238,937,511
-
Put/Call ratio
-
46%
-
Price per share
-
$12.28
-
Number of holders
-
215
-
Value change
-
+$32,280,106
-
Number of buys
-
114
-
Number of sells
-
86
Institutional Holders of Syndax Pharmaceuticals Inc - Common Stock, par value $0.0001 per share (SNDX) as of Q1 2025
As of 31 Mar 2025,
Syndax Pharmaceuticals Inc - Common Stock, par value $0.0001 per share (SNDX) was held by
215 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
100,841,762 shares.
The largest 10 holders included
BlackRock, Inc., Kynam Capital Management, LP, VANGUARD GROUP INC, Eversept Partners, LP, Point72 Asset Management, L.P., STATE STREET CORP, GOLDMAN SACHS GROUP INC, CITADEL ADVISORS LLC, BANK OF AMERICA CORP /DE/, and MORGAN STANLEY.
This page lists
216
institutional shareholders reporting positions in this security
for the Q1 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.